spacer
home > pmps > summer 2017 > of paramount importance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Of Paramount Importance

Parenterals are an important segment within the drug delivery field, assuming approximately 30% of the market share. One factor driving this is the substantial emergence of new therapeutic antibodies and advancements in biotechnology, resulting in many improved medications that have led to enhancements in patient wellbeing and life expectancy (1,2).

The realisation and proliferation of recombinant DNA technology led to the development of protein drugs. In particular, the development of monoclonal antibodies (mAbs) as drugs has increased significantly over the past few years. From 2014 onwards, 64 mAbs have been approved, are pending or are in review in Europe and the US. Additionally, more than 200 are in a clinical study stage. As explained by Dr Steven J Shire, mAbs are very specific, binding to a single antigen target, which may lead to fewer side effects than small molecule drugs (3).

Product Control


Biopharmaceuticals are frequently administered through injection using pre-filled syringes (PFSs); however, proteins are inherently unstable, sensitive to heat and oxidisation and have the propensity to aggregate (4-6). This generates the need to control the stability and quality of the drug product (DP), mitigating possible interactions in a risk-based approach for preventing effects on drug efficacy, pharmacokinetics and clinical consequences affecting patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
William Dierick is Director of Technology Development Global Pharmaceutical Solutions at Terumo: a global R&D company that offers drug delivery devices and injection technology, cardiology and cardiovascular systems, transfusion, patient monitoring and clinical systems. With 40 years of experience in the medical and pharma sector, he has held various positions in the company, covering quality assurance, production and product development to marketing, corporate planning and business development. William serves as expert of ISO/TC76 and ISO/TC84 and is an active member of MedTech Europe and volunteer at PDA.

Dr Piet Christiaens is Scientific Director at Toxikon Europe where he develops analytical methods and protocols for E&L studies for the medical and pharma industries. He oversees all laboratory operations at the company and is supporting the European business development. Piet received his PhD from the Analytical Chemistry Department of the University of Leuven, Belgium, in 1991. 

Dr Wim Van Rossom graduated with an MSc in organic chemistry in 2006 and received his PhD in 2010 from the Catholic University of Leuven, Belgium. In 2011, he moved to Japan where he spent two years as a Postdoctoral Fellow at the National Institute for Materials Science designing synthetic approaches towards macrocyclic structures. He was selected by the European Commission for a Marie Curie Career Integration Grant in 2013 to continue his research at the University of Southampton, UK, as Research Fellow on the topics of supramolecular anion recognition and transmembrane anion transport. Since 2015, he has been Study Director at Toxikon Europe, focusing on E&L studies in parenteral applications. 
spacer
William Dierick
spacer
spacer
spacer
Dr Piet Christiaens
spacer
spacer
spacer
Dr Wim Van Rossom
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement